WHO: New crowns with the antiviral drug Redsyvirus are not recommended

GENEVA, Nov. 20 (Xinhua Liu Qu) The World Health Organization said in a statement on the 20th, no matter how serious the hospital condition of the new crown patients, do not recommend the use of the antiviral drug Redsivir treatment, because there is no evidence that the drug can improve patient survival rate or reduce the patient's demand for ventilators.
statement said a WHO guidelines development team of international experts, published in the British Medical Journal on the 20th, noted that Redsyve is increasingly being used to treat new crown inpatients, but its role in clinical practice remains unclear.
group of experts came to this conclusion after assessing and comparing the efficacy of several new crown drugs. The assessment covered four international randomized trials involving data on more than 7,000 new crown inpatients.
expert group noted that while it has not been possible to conclude that Redsyves is completely useless, there is no data to prove that the drug can significantly improve the effectiveness of treatment in patients. Taking into account the potential for serious side effects and its high cost and resource consumption, the Group decided not to recommend the use of the drug, but also supported the continuation of the Redsyves assessment with a view to providing conclusive evidence of the use of the drug in specific patient groups.
is an antiviral drug developed by Gilead Technologies inc. to treat diseases such as Ebola haemorrhagic fever and Middle East Respiratory Syndrome. The U.S. Food and Drug Administration approved Redsyvir in October for hospitalization in adult patients with new crowns and children over 12 years of age weighing more than 40 kilograms, making it the first new crown drug approved by the FDA.